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Introduction
Pulmonary infections are incredibly dangerous for humans, with the
risks increased for those that are immunocompromised.¹ The
development of drug-resistant fungal strains has created a critical issue
with pulmonary infections in public health. Specifically, pulmonary
aspergillosis caused by fungi Aspergillus is the focus of this study.
Currently, for aspergillosis treatment, antifungals are in intravenous and
oral forms.² Antifungal drugs are mostly hydrophobic and have little
water solubility. Therefore, low water solubility restricts high
concentrations of the antifungal drug to be delivered to the lung and
has low circulatory times. Here, we use mesoporous silica
nanoparticles (MSNs) as nanocarriers to deliver antifungal drug,
Amphotericin B (AmpB).³ The nanocarrier allows for the low water
soluble AmpB to be delivered in higher dosage to Aspergillus. MSNs
were synthesized using a template method. The AmpB loading and
release was observed using Fourier-Transform Infrared spectroscopy
(FTIR), UV-visible spectroscopy, and thermogravimetric analysis. In
order to test the efficacy of the released AmpB, its antifungal activity
was observed against Aspergillus flavus (A. flavus). Colorimetric
antifungal assay and colony counting was performed to determine
antifungal efficacy.

Encapsulation of AmpB in MSNs: In order to load the MSNs with
AmpB: 1 mg/mL of AmpB in DMSO was combined with 10 mg of the
dried MSNs. This mixture was then left to stir overnight at 400 rpm. It
was centrifuged at 12,000 rpm for 10 minutes, in order to obtain the
AmpB@MSNs. In order to remove the excess drugs, the
AmpB-loaded MSNs were washed three times with water.
Characterization of AmpB@MSNs: The size and surface charge of
the nanoparticles was determined through dynamic light scattering
(DLS). Transmission electron microscopy was used to capture
images of the nanoparticles.
Determining Release of AmpB: AmpB release from MSN was
observed at 396 nm using UV-vis spectroscopy.
Released AmpB efficacy on A. flavus: Tetrazolium-based MTT
assay was used as a colorimetric assay, and a colony counting assay
was used to determine the released AmpB efficacy.

Results and Discussion
AmpB drug loaded MSNs (AmpB@MSNs) were ~ 280 nm in
diameter (see Table 1). The surface charge of the nanocarrier was 19 mV. AmpB has a zeta potential of -19 mV, and the MSN has a
zeta potential of -23 mV. Successful loading of AmpB in MSN can be
visualized through the reduction of zeta potential from -23 mV in
MSN to -19 mV in AmpB@MSN.
AmpB loading was calculated to be 625 µg in 1 mg of MSN (see
Table 2). The encapsulation efficiency and drug loading capacity was
63% and 69%. Even though high loading of the drug was seen,
AmpB release was remarkably low (<5%) (see Figure 1). The
released AmpB did not have sufficient antifungal activity to afford
minimum inhibitory effect on A. flavus compared to the free drug
AmpB.
Drug Loading - AmpB@MSN

Size and surface charge characterization of
AmpB@MSNs
Sample

Size (Volume,
nm)

-19.47 ± 0.47

MSN

-23.1 ± 0.781
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Encapsulation Drug Loading AmpB per mg
Efficiency
Capacity
MSN
62.5%

68.7%

625 µg

0.614 ± 0.051 -19.0 ± 0.2

Table 1. Size and surface charge of AmpB@MSN.

Scheme 1. Template Method for synthesis of MSN.

Table 2. AmpB drug loading in AmpB@MSN

Figure 1. AmpB release profile from AmpB@MSN.
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Scheme 2. Liposome encapsulated AmpB loaded MSNs delivering AmpB to Aspergillus.

Synthesis of MSNs: Cetyl trimethyl ammonium bromide (CTAB)
solution was created by dissolving 204 mg, 4 mmol of CTAB in 140
mL of water. A solution of 1688 µL, 7.6 mmol TEOS, and 1688 µL
ammonium hydroxide, 25% v/v% was added dropwise to the CTAB
solution. The solution was then stirred at 400 rpm at room
temperature overnight. The next day, the MSNs were centrifuged at
7,830 rpm for 10 minutes. The MSNs were then redispersed in
water, centrifuged, and redispersed in 50 mL of ethanol that
contained 200 µL conc. HCl. This removed the CTAB surfactant,
and the mixture was then stirred at 60 ℃ overnight. The MSNs were
then purified by X3 centrifugation at 7,830 rpm for 10 minutes, and
finally dispersed in water.
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